Quantcast

Industry news that matters to you.  Learn more

KineMed Announces Biomarker Discovery Collaboration with GSK

KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable more informed and timely decision-making in clinical trials of compounds for muscle wasting, fibrosis and metabolic diseases.

PrognosDx Health and Accium BioSciences Enter Into Collaborative and Research Agreement to Develop Clinical Tests Based on Histone Biomarkers

PrognosDx Health, a pioneering company in cancer epigenetics, announced today that Dr. Jeffrey L. Wolf has joined its scientific advisory board. An expert in multiple myeloma and other hematopoietic malignancies, Dr. Wolf also specializes in bone marrow transplantation for treatment of a variety of cancers. Dr. Wolf is the Director of the Multiple Myeloma Program in the Division of Hematology and Oncology at the Helen Diller Family Comprehensive Cancer Center and a Clinical Professor of Medicine at UCSF.

It was also announced that PrognosDx Health and Accium BioSciences (Seattle, Washington) have entered into a collaboration agreement aimed at co-developing and commercializing a series of high-value predictive histone biomarker tests. The collaboration combines the expertise and breakthrough epigenetic platform technology of PrognosDx with the accelerator mass spectrometry (AMS) platform of Accium BioSciences.

Lupus Experts Gather at the FDA to Explore Potential for Biomarkers to Accelerate Clinical Trials

Biomarkers, potential indicators to monitor disease progress and treatment success, are among the most challenging and critical areas of lupus research according representatives of industry, academia, government and advocacy attending a U.S. Food and Drug Administration workshop this week. The meeting was convened to focus on the development of biomarkers to predict acute worsening of disease, called a flare, and their potential for accelerating lupus clinical trials and new drug approvals.

National Parkinson Foundation Awards More Than $1 Million for Research

The National Parkinson Foundation (NPF) has awarded more than $1 million dollars in clinical research projects in 2011. Through NPF’s individual investigators awards program, NPF is supporting work to advance three key areas of Parkinson’s disease (PD): 1) an advanced biomarker study, 2) a clinical trial to treat memory impairment, and 3) a study of the effectiveness of a treatment for sleep apnea in PD.

Pacific Biomarkers Establishes Science Board to Advise on Clinical Biomarker Services

Pacific Biomarkers today announced the establishment of a Scientific Advisory Board to help it evaluate new technologies and opportunities in the clinical research space.